Suburban Research Associates

Media, Pennsylvania 19603

2 studies enrolling now · 90 studies all time

What they study most

Adult Attention Deficit Hyperactivity Disorder, Alzheimer Disease (AD), Alzheimer's Disease, Anhedonia, Anxiety Disorder, Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit/Hyperactivity Disorder, Autism, Autism Spectrum Disorder, Autism Spectrum Disorders, Binge Eating Disorder, Bipolar Disorder

Studies at this site

• Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) — Recruiting now
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder — Recruiting now
• ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) — Running, not enrolling
• A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults — Running, not enrolling
• A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults — Running, not enrolling
• A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome — Completed
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) — Completed
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
• Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults — Completed
• A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder — Completed
• ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) — Completed
• A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD — Running, not enrolling
• A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder. — Completed
• A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Stopped early
• Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) — Completed
• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
• A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD — Completed
• A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant — Stopped early
• A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome — Completed
• Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder — Completed
• Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD — Running, not enrolling
• Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder — Completed
• Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression — Completed
• A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy — Completed
• An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome — Running, not enrolling
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) — Completed
• A Study of JNJ-55308942 in the Treatment of Bipolar Depression — Completed
• A Study of JNJ-61393215 in the Treatment of Depression — Completed
• A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy — Completed
• A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease — Completed
• Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease — Completed
• Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) — Completed
• Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension — Completed
• A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine — Completed
• Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents — Completed
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease — Completed
• Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) — Completed
• Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain — Completed
• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® — Stopped early
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• Open Label Extension in Adults With Binge Eating Disorder (BED) — Completed
• SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder — Completed
• SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder — Completed
• A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression — Stopped early
• A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD) — Stopped early
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) — Completed
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) — Stopped early